Clinical Trials
Clinical trial of antiviral HIV/AIDS therapeutic in HIV-positive patients initiated
Published in Vaccine Weekly, November 9th, 2005
The objectives of the trial are to evaluate the safety, toxicity, pharmacokinetic profile and initial clinical activity of KP-1461. The trial is being conducted at several HIV treatment centers in the United States.
KP-1461 is a first-in-class therapeutic designed to overcome the problem of drug resistance that has emerged with approved HIV treatments. KP-1461 has a novel mechanism of action designed to eliminate the human immunodeficiency virus (HIV) by selectively increasing its natural mutation rate...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2005-11-09)
More Articles from Vaccine Weekly
- Meningitis Vaccine
Method is developed to determine avidity for H. influenzae antibodies - Pyelonephritis Vaccine
E. coli K13 diphtheria toxoid conjugate was immunogenic against pyelonephritis - Virology Vaccine
Interferons act to allow clonal expansion in response to viral infection - Yellow Fever Vaccine
Agency is developing methods to evaluate yellow fever vaccine centers - Anticancer Agents
Development of histone deacetylase inhibitors as anticancer agents reviewed - Apoptosis
Low-dose cisplatin protects neuroblastoma SH-SY5Y cells from paclitaxel-induced apoptosis - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
